Safety and efficacy of dual therapy with daclatasvir and asunaprevir for older patients with chronic hepatitis C-Reference-Cited by-同舟云学术

Safety and efficacy of dual therapy with daclatasvir and asunaprevir for older patients with chronic hepatitis C

Published:2016-09-08 Issue:4 Volume:52 Page:504-511
ISSN:0944-1174
Container-title:Journal of Gastroenterology
language:en
Short-container-title:J Gastroenterol

Author:

Morio Reona,Imamura Michio,Kawakami Yoshiiku,Morio Kei,Kobayashi Tomoki,Yokoyama Satoe,Kimura Yuki,Nagaoki Yuko,Kawaoka Tomokazu,Tsuge Masataka,Hiramatsu Akira,Nelson Hayes C.,Aikata Hiroshi,Takahashi Shoichi,Miki Daiki,Ochi Hidenori,Mori Nami,Takaki Shintaro,Tsuji Keiji,Chayama Kazuaki

Funder

AMED

Publisher

Springer Science and Business Media LLC

Subject

Gastroenterology

Link

http://link.springer.com/content/pdf/10.1007/s00535-016-1255-4.pdf

Reference30 articles.

1. Armstrong GL, Wasley A, Simard EP, et al. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med. 2006;144:705–14.

2. Huang CF, Yang JF, Dai CY, et al. Efficacy and safety of pegylated interferon combined with ribavirin for the treatment of older patients with chronic hepatitis C. J Infect Dis. 2010;201:751–9.

3. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975–82.